NextCure, Inc. (NasdaqGS: NXTC)
Health Care · Biotechnology · US
$6.24
-13.09% today · -42.3% 1Y
NextCure, Inc. (NasdaqGS: NXTC) operates in the Biotechnology industry within the Health Care sector. The company is valued at $28.56M and employs 40 people.
Over the last twelve months the share price has lost 42.3%, trading between 1.55 and 15.74.
Tweenvest scores NextCure, Inc. across four factors: quality 37/100, value 78/100. Its strongest factor is value.
NXTC price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $28.56M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -9.94
- Dividend yield
- —
- Beta (5Y)
- 1.35
- 52-week high
- $15.74
- 52-week low
- $1.55
- Avg volume (3M)
- —
- Shares outstanding
- 4.58M
- Employees
- 40
- Next earnings
- —
About NextCure, Inc.
NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metastatic solid tumors. Additionally, NextCure is progressing NC410 through Phase I studies; this novel immunomedicine is engineered to counteract immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR-1). Another asset, NC762, is an immunotherapeutic designed to target the human B7 homolog 4 protein (B7-H4). Furthermore, NC525, a distinct LAIR-1 antibody, is undergoing preclinical assessment for its potential efficacy against acute myeloid leukemia, specifically targeting blast cells and leukemic stem cells. Beyond these specific pipeline candidates, NextCure's broader research and development efforts encompass the preclinical evaluation of other promising immunomodulatory antibodies and molecules. The company operates under a licensing agreement with Yale University. NextCure, Inc. was established in 2015 and maintains its corporate headquarters in Beltsville, Maryland.
- ISIN
- US65343E2072
- Founded
- 2015
- Listed since
- May 9, 2019
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Quratis Inc.KOSDAQ: A348080 | $29.12M | ₩3,310.00 | -11.50% |
| Microbix Biosystems Inc.TSX: MBX | $29.05M | CA$0.30 | -3.23% |
| TransCode Therapeutics, Inc.NasdaqCM: RNAZ | $28.78M | $1.70 | -8.60% |
| Amplia Therapeutics LimitedASX: ATX | $28.57M | AU$0.08 | -23.81% |
| CEL-SCI CorporationNYSEAM: CVM | $28.32M | $1.61 | -0.62% |
| Intervacc AB (publ)OM: IVACC | $28.25M | Skr0.82 | -7.44% |
| Matricelf LtdTASE: MTLF | $27.79M | ₪2.60 | +4.20% |
| Zenotech Laboratories LimitedBSE: 532039 | $27.69M | Rs43.06 | -0.02% |
Figures last refreshed Oct 18, 2026.